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Abstract
Background:  Nasopharyngeal carcinoma (NPC) is a head and neck malignancy with high
occurrence in South-East Asia and Southern China. Recent findings suggest that epigenetic
inactivation of multiple tumor suppressor genes plays an important role in the tumourigenesis of
NPC. BRD7 is a NPC-associated bromodomain gene that exhibits a much higher-level of mRNA
expression in normal than in NPC biopsies and cell lines. In this study, we explored the role of
DNA methylation in regulation of BRD7 transcription.
Methods:  The presence of CpG islands within BRD7 promoter was predicted by EMBOSS
CpGplot and Softberry CpGFinder, respectively. Nested methylation-specific PCR and RT-PCR
were employed to detect the methylation status of BRD7 promoter and the mRNA expression of
BRD7 gene in tumor cell lines as well as clinical samples. Electrophoretic mobility shift assays
(EMSA) and luciferase assay were used to detect the effects of cytosine methylation on the nuclear
protein binding to BRD7 promoter.
Results: We found that DNA methylation suppresses BRD7 expression in NPC cells. In vitro
DNA methylation in NPC cells silenced BRD7 promoter activity and inhibited the binding of the
nuclear protein (possibly Sp1) to Sp1 binding sites in the BRD7 promoter. In contrast, inhibition of
DNA methylation augments induction of endogenous BRD7 mRNA in NPC cells. We also found
that methylation frequency of BRD7 promoter is much higher in the tumor and matched blood
samples from NPC patients than in the blood samples from normal individuals.
Conclusion: BRD7 promoter demethylation is a prerequisite for high level induction of BRD7
gene expression. DNA methylation of BRD7 promoter might serve as a diagnostic marker in NPC.
Background
NPC is a head and neck malignancy with high occurrence
in South-East Asia and Southern China [1,2]. The devel-
opment of this EBV-associated cancer may involve cumu-
lative genetic and epigenetic changes in a background of
predisposed genetic and environmental factors [3,4].
Genome-wide studies have unraveled multiple chromo-
somal abnormalities with involvement of specific onco-
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genes and tumor suppressor genes [5,6]. BRD7 has been
recently identified as a bromodomain gene in NPC cells
by cDNA Representational Difference Analysis (cDNA
RDA) [7]. As a member of the bromodomain genes fam-
ily, BRD7 may be considered as a component of chroma-
tin remodeling complexes which possess histone
acetyltransferase activity [8,9]. Together with E1B-AP5,
BRD7 functions as an inhibitor of basic transcription in
several viral and cellular promoters in the nucleus [10].
An alternative role of BRD7 arises from the evidence that
BRD7 exhibits a much higher level of mRNA expression in
normal nasopharyngeal epithelia than in NPC biopsies
and cell lines [11,12]. Indeed, over-expression of BRD7 in
NPC cells can effectively inhibit cell growth and cell cycle
progression from G1 to S phase by transcriptional regula-
tion of some key cell cycle related genes [13-15]. Our pre-
vious studies revealed the full-length promoter -404/+46
of BRD7 gene, and showed that Sp1 specifically bound to
BRD7 promoter [16]. However, little is known about the
down-expression of BRD7 in NPC cells. In this report, we
reveal that DNA methylation results in the suppression of
BRD7 expression in NPC cells. BRD7 promoter activity is
regulated by methylation of CpG sites with the (G+C)-rich
promoter region. DNA methylation inhibitor, 5-Aza-CdR,
up-regulates BRD7 expression in NPC 5–8F cells. More
importantly, the methylation frequency of BRD7 pro-
moter is much higher in the tumor and matched blood
samples from NPC patients than that in the blood sam-
ples from normal individuals. These results will be helpful
in further understanding the transcription-repression
mechanism of the BRD7 gene in NPC cells and the estab-
lishment of noninvasive approach in the early detection
and surveillance of NPC.
Methods
Cell culture and antibodies
Most of the cell lines used in this study was from the
American Type Culture Collection (ATCC). NPC CNE1,
5–8F (high tumorigenic and metastatic ability) and 6–
10B (tumorigenic, but lacking metastatic ability) cell lines
were provided by the Cancer Center of Sun Yet-Sen Uni-
versity, (Guangzhou, China). NPC HNE1 cells were pro-
vided by Cancer Research Institute of Central South
University (Hunan, China). COS7 and BHK-21 cells were
cultured in Dulbecco modified Eagle medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 100 U/ml penicillin and 100 μg/ml strepto-
mycin at 37°C, 5% CO2. HNE1, CNE1, 6–10B, 5–8F,
SW480 and Hella cells were cultured in RPMI1640
medium containing 10% FBS.
Bioinformatics
The presence of CpG islands within the upstream region
spanning from -1 to -2000 bp of BRD7 gene was analyzed
with EMBOSS (European Molecular Biology open soft-
ware Suite http://www.ebi.ac.uk/emboss/cpgplot pro-
gram CpGplot and Softberry CpGFinder program http://
www.softberry.com/berry.phtml?topic=CpG island,
respectively.
Construction of plasmids
pGL3-404/+46 was generated as previously described.
pGL3-404/+46/GFP was generated by replacing the luci-
ferase gene of pGL3-enhancer with enhanced green fluo-
rescence protein (EGFP) as follows: EGFP coding region
was amplified by PCR using primers 5'-GACTTTC-
CAAAATGTCGTAACAACTCC-3' (forward) and 5'-
GGCTCTAGATTACTTGTACAGCTCGTC-3' (reverse) with
pEGFP-C2as template, cut with double restriction enzyme
NcoI and XbaI, then cloned into vector fragment of pGL3-
404/+46 which was cut with the same restriction enzymes
NcoI and XbaI to release the luciferase coding region.
Luciferase assay
Luciferase assay was performed as previously described
[16]. Briefly, 4 × 105 cells were seeded in each well of 12-
well plates 24 h prior to transfection, then transfected
with 0.5 μg of various BRD7 promoter constructs and 0.25
μg pSV40 β-galactosidase per well by Lipofectamine 2000
Reagent (Invitrogen) according to manufacturer's instruc-
tion. Luciferase activity was measured in cell lysates 38 h
after transfection using Luciferase Assay kit (Promega). β-
galactosidase activity was measured in cell lysates by β-
galactosidase Enzyme Assay System (Promega). Experi-
ments were repeated at least three times with three repli-
cates per sample. Results were normalized against β-
galactosidase activity.
Direct GFP fluorescence assay
4 × 105 cells were seeded in each well of 12-well plates 24
h prior to transfection. Next day, every well was trans-
fected with 0.5 μg of pGL3/-404,+46/EGFP or CH3-pGL3/
-404,+46/EGFP in by using Lipofectamine 2000 Reagent
according to manufacturer's instruction. EGFP fluores-
cence was observed 38 h after transfection using an AX-80
analytical microscope system (Olympus, Tokyo, Japan).
RT-PCR
RT-PCR was performed as previously described [16]. The
single-stranded cDNA was amplified by using primers as
follows: BRD7 primer (forward) 5'-CAAGCTCTT-
TAGCCAAACAAGAA-3', (reverse) 5'-TCATTCCTGAGT-
GCAACAGC-3'; GAPDH primer (forward) 5'-
TCTAGACGGCAGGTCAGGTCCACC-3', (reverse) 5'-
CCACCCATGGCAAATTCCATGGCA-3'. PCR was carried
out for 28 cycles using a step cycle of 94°C for 40 s, 58°C
for 40 s, 72°C for 1 min, followed by 72°C for 10 min.
GAPDH primer was added to the reactions at the end of
the fifth cycle.BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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Nested methylation-specific PCR analyses
The DNA methylation status was established by PCR anal-
ysis of bisulfite-modified genomic DNA, which induces
chemical conversion of unmethylated, but not methyl-
ated, cytosine to uracil, using two procedures. First, meth-
ylation status was analyzed by bisulfite genomic
sequencing of both strands of the corresponding CpG
islands. The second analysis used methylation-specific
PCR using primers specific for either the methylated or
modified unmethylated DNA. Methylation-specific
primer (forward): 5'-AGTTTGAGCGGTGGATTTCGTTTC-
3', (reverse) 5'-GGTTCGGTCGGATATGGGTAAGAAG-3';
Unmethylation-specific primer (forward): 5'-AAAGATGA-
GAGTTTGAGTGGTGGATTTT-3', (reverse) 5'-GGGGTTT-
GGTTGGATATGGGTAAGAAG-3'.
Sodium bisulfite modification and genomic sequencing
Genomic DNA was extracted from blood or cultured cells
with or without a 72 h pretreatment with 5-Aza-CdR,
using the DNA-easy kit (Qiagen) according to the manu-
facturer's instructions. Two μg of DNA was denatured in
50 μl of 0.3 M NaOH for 15 min at 37°C. For the chemical
modification of DNA, 520 μl of 3 M sodium bisulfite
(Sigma) and 30 μl of 10 mM hydroquinone (Sigma) were
added to the DNA solution and the samples were mixed,
overlaid with mineral oil, and incubated at 50°C over-
night. Modified DNA was purified with the Wizard DNA
Clean-up system (Promega) and eluted in water. As a final
step, NaOH was added to a final concentration of 0.3 M,
and the samples were incubated for 5 min at room tem-
perature. DNA was precipitated by ethanol and resus-
pended in water. The sequence of interest in the bisulfite-
reacted DNA was PCR-amplified in a reaction mixture
containing dNTPs, PCR buffer, Taq enzyme, and primers.
For each reaction, 1 μl (~50 ng) of bisulfited DNA was
used in 25 μl reaction volume. DNA fragments were gel-
purified with the QIAquick Gel Extraction kit (Qiagen)
cloned into pGEM/T-easy vector (Invitrogen). Clones
with appropriate sized inserts were sequenced.
In vitro DNA methylation and transient transfection
The methylated plasmids (Met-pGL3/-404,+46 and Met-
pGL3/-404,+46/GFP) were generated by incubating 40 μg
of plasmid DNA (pGL3/-404,+46 and pGL3/-404,+46/
GFP) with 100 units SssI methylase in reaction buffer con-
sisting of 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1
mM dithiothreitol, pH 7.9, and 160 μM S-adenosylme-
thionine according to the manufacturer's instructions
(New England Biolabs, Inc.). Reactions were carried out at
37°C overnight. Complete methylation was verified by
digestion with the methylation-sensitive restriction
enzyme HpaII. Only plasmids that showed a complete
protection from HpaII digestion were used in the transfec-
tion experiments. The methylated plasmid DNA was puri-
fied by the Wizard DNA Clean-up system (Promega) and
transfected into COS7 and 5–8F cells in parallel with the
unmethylated pGL3/-404,+46 and pGL3/-404,+46/GFP,
respectively. Luciferase activity was analyzed at 38 h after
transfection.
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared, quantified, and used for
EMSA with double strand probes or competitors as
described previously [16]. The methylated -353/-337 and
-330/-317 oligonucleotide were prepared by incubating
20  μg of unmethylated -353/-337 (Sense: 5'-GATC-
CCGCCCCGGCCCCGCCCTCGG-3', anti-sense:5'-
CCGAGGGCGGGGCCGGGGCGGGATC-3') and -330/-
317 (Sense: 5'-CGGCCCCGCCCCCGGCCCGCGAGCT-
3', anti-sense: 5'-AGCTCGCGGGCCGGGGGCG-
GGGCCG-3') with 80 units of SssI CpG methylase at
37°C overnight. The reaction mixture was then heated at
65°C to inactivate the methylase, purified by polyacryla-
mide gel electrophoresis, and concentrated with Centri-
con 3 microconcentrators. Nuclear extracts were
incubated for 20 min on ice in the presence or absence of
unlabeled competitor oligonucleotides followed by the
addition of the end-labeled probe and 15 min incubation
on ice.
5-Aza-CdR and TSA treatment
For the 5-Aza-CdR treatment, DNA methyltransferase
inhibitor, 5-Aza-CdR, was added to 2 × 106 cells at final
concentrations from 1.875 to 15 μM for 72 h. For trichos-
tatin A (TSA) treatment alone, deacetylase inhibitor TSA
was added to 2 × 106 cells at final concentrations from 150
to 5000 nM for 48 h. For the treatment of 5-Aza-CdR com-
bined with TSA, 1000 nM of TSA was added to 2 × 106 cells
for 48 h at the end of the treatment of 3.75 μM 5-Aza-CdR.
Tumor and blood samples
All samples were collected from the Xiangya Hospital of
Central South University and the Hunan Tumor Hospital,
Changsha, Hunan, China. All patients were diagnosed by
pathological examination. Totally 18 NPC patients and
16 normal individuals were used in this study. Written
informed consent was obtained from all studied partici-
pants. The study was approved by the ethical review com-
mittees of the appropriate institutions. Five-to-10 ml
peripheral blood samples were taken from each individ-
ual.
Results
A CpG island is overlapped with BRD7 promoter
After depositing 2000-bp of the upstream gDNA sequence
of BRD7 gene, a CpG island spanning from -418 to -56-bp
was identified by using EMBOSS software (Fig. 1A, B),
whereas a CpG island spanning from -374 to -4-bp was
identified by using Softberry CpG Finder Program (Fig.
1B). The sequences of the CpG islands predicted by theseBMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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Overlapping of CpG island with BRD7 promoter Figure 1
Overlapping of CpG island with BRD7 promoter. (A) A CpG island spanning from -481 to -56 bp upstream of BRD7 
gene identified by EMBOSS CpGplot program. (B) Schematic representation of BRD7 promoter -404/+46 (marked with the 
square) and the CpG island in the upstream sequence of BRD7 gene. The CpG island (hatched box) of BRD7 gene was pre-
dicted by EMBOSS CpGplot program whereas the CpG island (diamond-shaped box) of BRD7 gene was predicted by the Soft-
berry CpGFinder program. The translation start site is position +1 and the rest of the sequence is numbered relative to it.BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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two programs overlapped with each other, as well as with
the sequences of BRD7 promoter (Fig. 1B). The overlap-
ping region was a 317-bp-long sequence (-373 to -56 bp).
Down-regulation of BRD7 gene expression in NPC cells is 
due to partly methylation of BRD7 promoter
Previous studies have shown that BRD7 was down-regu-
lated in NPC biopsies and NPC cell lines [11]. Genomic
DNA obtained from various cell lines was treated with
sodium bisulfite under conditions where cytosines are
converted to uracils, while methylated cytosines remain
unmodified. By using methylation-specific and unmethyl-
ation-specific primers described in Fig. 2A, we performed
methylation-specific PCR and revealed that HNE1, CNE1,
6–10B, 5–8F, SW480 and Hela cells exhibited a methyl-
ated BRD7 promoter, whereas no methylation of BRD7
promoter was found in COS7 and BHK-21 cells (Fig. 2B).
RT-PCR showed down-expression of BRD7 mRNA in
HNE1, CNE1, 6–10B, 5–8F, SW480 and Hela cells as
compared to COS7 and BHK-21 cells. The data indicated
that the mRNA expression of BRD7 gene is inversely cor-
related to the methylation status of BRD7 promoter in
NPC cell lines.
DNA methylation inhibitors 5-Aza-CdR augments 
endogenous mRNA and reverses the methylation status of 
BRD7 promoter in NPC cells
To determine whether DNA methylation and chromatin
modification contribute to the regulation of BRD7 expres-
sion in NPC 5–8F cells, BRD7 mRNA level was measured
in the presence of various concentrations of 5-Aza-CdR
alone, TSA alone or 5-Aza-CdR combined with TSA. As
shown in Fig. 3A, BRD7 mRNA expression in NPC 5–8F
cells was increased by 7 fold by 5-Aza-CdR (3.75 μM) and
by 4 fold by TSA (1000 nM) relative to controls. The addi-
tion of TSA to 5-Aza-CdR did not result in additional
enhancement of the BRD7 gene expression in NPC 5–8F
cells. Methylation-specific PCR results showed that as low
as 3.75 μM of 5-Aza-CdR was sufficient to completely
reverse the methylation of BRD7 promoter in 5–8F cells
(Fig. 3B). These data suggest that hypomethylation
increased BRD7 mRNA expression in 5–8F cells. There-
fore, the restoration of BRD7 induction by 5-Aza-CdR or
TSA treatment could be related a direct demethylation of
BRD7 promoter.
Bisulfite treatment and sequencing analysis identifies 
methylated cytosines in BRD7 promoter
Sodium bisulfite deaminates unmethylated cytosine to
uracil in single-stranded DNA under conditions in which
the 5-methylcytosine remains nonreactive. Thus, all cyto-
sine residues remaining at the time of sequencing repre-
sent cytosines that were methylated in the original DNA
sequence. Genomic DNA from 5–8F cells treated with or
without 3.75 μM of 5-Aza-CdR was analyzed. Sequencing
analysis showed that the cytosines (labeled with *) at -
374, -362, -352, -329, -226, -9, -5 bp were methylated in
BRD7 promoter of 5–8F cells and were unmethylated in
5–8F cells treated with 3.75 μM of 5-Aza-CdR (Fig. 4B).
Two "C" (labeled with *) at -260 and -170 bp appear. It
could not be due to CpG methylation, possibly due to
insufficient bisulfited treatment.
Cytosine methylation inhibits nuclear protein binding to 
BRD7 promoter
Cytosine methylation in the promoter region, when
present within regulatory elements, could potentially
interfere with binding of specific transcription factors to
these motifs. Our previous studies confirmed that the
MYC-MAX binding site at -260/-246 was non-specific
[16]. To investigate whether cytosine methylation within
Sp1 binding sites at -353/-337 and -330/-317 interfere
with nuclear factor binding, we compared the binding
abilities in EMSA reactions of a 20-bp oligomer (nucle-
otides -353/-337 and -330/-317), which contained the
two different Sp1 elements and neighboring cytosines, in
unmethylated and methylated forms. First we examined
the abilities of unmethylated and methylated -353/-337
to compete with the unmethylated -353/-337 probe in
binding to nuclear proteins from 5–8F cells. As seen in
Fig. 5A, two sequence-specific gel shift complexes were
observed with labeled unmethylated -353/-337 as a probe
(lane 1 of Fig. 5), but no complex was formed with
labeled methylated -353/-337 as a probe (lane 2 of Fig. 5).
In competition EMSA reactions, 50-fold excess of unla-
beled unmethylated -353/-337 oligomers were sufficient
to completely inhibit complex formation (lane 3, 4 of Fig.
5), but none of the DNA-protein bands were inhibited by
the addition of a 100-fold excess of unlabeled methylated
-353/-337 oligomers (lane 5, 6 of Fig. 5), suggesting that
the unmethylated -353/-337 oligomer binds activated
protein. Then we compared the abilities of unmethylated
and methylated -330/-317 oligomers to bind nuclear pro-
teins from 5–8F cells in EMSA reactions using labeled
unmethylated -330/-317 or methylated -330/-317 as
probes. A strong and a weak DNA-protein complexes were
formed with labeled unmethylated -330/-317 as probes
(lane 7 of Fig. 5), whereas no DNA-protein complexes
were formed with methylated -330/-317 as probes (lane 8
of Fig. 5). In the competition assay, both of them were
completely inhibited with cold unmethylated -330/-317
(lane 9 of Fig. 5), but none of them were inhibited by cold
methylated -330/-337 (lane 11, 12 of Fig. 5). These results
suggested that methylation of cytosines at -353/-337 and
-330/-317 significantly inhibited nuclear protein (possi-
bly Sp1) binding to BRD7 promoter.BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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Down- regulation of BRD7 in NPC cells is due to partial methylation of BRD7 promoter Figure 2
Down- regulation of BRD7 in NPC cells is due to partial methylation of BRD7 promoter. (A) Map of the methyla-
tion- and unmethylation-specific primer in BRD7 promoter region. (B) PCR amplification of BRD7 promoter region by using 
methylation- and unmethylation-specific primer. PCR product was size-fractionated on agarose gels and bands visualized by 
ethidium-bromide staining of the gels. The presence of a PCR band in the lane "M" indicates methylated genes, while the pres-
ence of a PCR band in the lane "U" indicates unmethylated genes. (C) Detection of BRD7 mRNA expression in the cell lines by 
RT-PCR.BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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DNA methylation inhibitors 5-Aza-CdR augments endogenous mRNA expression of BRD7 gene and reverses the methylation  status of BRD7 promoter Figure 3
DNA methylation inhibitors 5-Aza-CdR augments endogenous mRNA expression of BRD7 gene and reverses 
the methylation status of BRD7 promoter. (A) RT-PCR amplification of BRD7 expression in 5–8F cells treated with 0–15 
μM 5-Aza-CdR, 150–450 nM TSA, and 7.5 μM 5-Aza-CdR combined with 300 nM TSA. (B) PCR amplification of BRD7 pro-
moter region with methylation- and unmethylation-specific primer by using modified gDNA from 5–8F cells in the presence of 
vehicle or indicated concentration of 5-Aza-CdR, TSA or 5-Aza-CdR combined with TSA. The presence of a PCR band in the 
lane "M" indicates methylated promoter fragment, while the presence of a PCR band in the lane "U" indicates unmethylated 
promoter fragment.BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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Bisulfite treatment and sequencing analysis identifies methylation of BRD7 promoter Figure 4
Bisulfite treatment and sequencing analysis identifies methylation of BRD7 promoter. (A) Representative 
sequencing graphs of BRD7 promoter region in 5–8F cells treated with or without 5-Aza-CdR. Modified and unmodified 
cytosines are indicated by arrows. (B) Schematic depiction of methylated cytosine in BRD7 promoter region. The Cytosine 
under the "*" in the dinucleotide CpG indicates methylated cytosines.BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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In vitro cytosine methylation of BRD7 promoter silence its 
activity
To investigate the effect of in vitro CpG methylation on
BRD7 promoter activity, we treated BRD7 promoter
reporter construct pGL3-404/+46, pGL3-404/+46/GFP
with SssI methylase. After confirming the complete meth-
ylation status with restriction enzyme HpaII (Fig. 6A),
Met-pGL3-404/+46, was transfected into COS7, BHK-21,
HNE1, CNE1, 6–10B, 5–8F, SW480 and Hela cells. As
shown in Fig. 6B, the luciferase activity driven by methyl-
ated BRD7 promoter was significantly decreased in all the
detected cell lines. To further confirm the effects of meth-
ylation on promoter activity, methylated GFP reporter
construct Met-pGL3-404/+46/GFP was transfected into 5–
8F cells. It exhibited no GFP fluorescence in 5–8F cell lines
(Fig. 6C). These results were consistent with that of the
luciferase assay, indicating that DNA methylation of
BRD7 promoter completely silenced its activity.
Frequent aberrant methylation of BRD7 promoter in NPC 
patients
We examined the methylation status of BRD7 promoter in
paired tumor biopsies and blood samples from NPC
patients and from normal individuals by using a methyl-
ation-specific PCR. Aberrant promoter methylation of
BRD7 gene was detected in 18 of 18 (100%) tumor biop-
sies (Top of Fig. 7A) and 18 of 18 (100%) (Bottom of Fig.
7A) matched blood samples of NPC patients, respectively.
In contrast, very weak promoter methylation of BRD7
gene was observed in 8 blood samples of 16 normal,
healthy, age-matched controls (Fig. 7B).
Discussion
BRD7 is a recently identified bromodomain gene. It
exhibits much higher-level of mRNA expression in normal
nasopharyngeal epithelia than in NPC biopsies and cell
lines [11,12]. Over-expression of BRD7 in NPC cells is
effective in inhibiting cell growth and cell cycle progres-
sion of NPC cells [13-15], but little is known about its
down-expression in NPC cells. In this study, we found
that BRD7 promoter is hemimethylated in a number of
NPC cell lines including HNE1, CNE1, 6–10B and 5–8F
cell lines, and that the methylation status of BRD7 pro-
moter is inversely proportional with BRD7 mRNA expres-
sion in NPC cells. Thus, pharmacological inhibition of
DNA methylation by 5-Aza-CdR enhanced BRD7 mRNA
Cytosine methylation inhibits transcription factor binding to its corresponding binding sites in BRD7 promoter Figure 5
Cytosine methylation inhibits transcription factor binding to its corresponding binding sites in BRD7 pro-
moter.Left panel: Comparison of the nuclear binding capabilities of unmethylated and methylated -353/-337 probes by EMSA. 
Results are representative of three independent experiments. Excess amounts of unlabeled unmethylated -353/-337, methyl-
ated -353/-337 were added as competitors. Right panel: Comparison of the nuclear binding capabilities of unmethylated and 
methylated -330/-317 probes by EMSA. Excess amounts of cold unmethylated -330/-317, methylated -330/-317 were added as 
competitors. NP: nuclear protein; Wt: wild type probe; Met: methylated probe; CH3-P: SssI methylase treated probe.BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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In vitro cytosine methylation of BRD7 promoter silence its activity in NPC cells Figure 6
In vitro cytosine methylation of BRD7 promoter silence its activity in NPC cells. (A) Detection of the methylation 
effects of Met-pGL3-404/+46 and Met-pGL3-404/+46/GFP by restriction enzyme cutting of HpaII. pGL3-404/+46 was used as a 
control. (B) Detection of the luciferase activity of methylated BRD7 promoter construct Met-pGL3/-404,+46 in COS7, BHK-
21, HNE1, CNE1, 6–10B, 5–8F, SW480, and Hela cells. Luciferase activity in COS7 and 5–8F cells is represented by black and 
gray histograms, respectively. All of the constructs were cotransfected with the SV40 β-galactosidase vector for normalizing 
transfection efficiency. Data are the means ± S.D. of three independent experiments. (C) Detection of the luciferase activity of 
modified GFP reporter construct Met-pGL3/-404,+46/EGFP in 5–8F cells. The full-length modified promoter construct pGL3/-
404,+46/EGFP was used as a positive control. 38 h after transfection, the signal of EGFP fluorescence driven by promoter frag-
ment -404/+46 or -266/-212 was observed by using an AX-80 analytical microscope system (Olympus, Tokyo, Japan).BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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expression in NPC cells. This is in agreement with previ-
ous studies that, indeed, hemimethylation is sufficient to
inhibit the expression of p16ink4A [17] and hMLH1 gene
[18] in HCT116 and HT29 cell lines, respectively. Numer-
ous studies have suggested that DNA methylation can
suppress gene transcription either by directly inhibiting
Detection of methylation frequency of BRD7 promoter in tumor biopsies and blood samples from NPC patients (A) as well as  blood samples from corresponding normal individuals (B) by methylation-specific PCR Figure 7
Detection of methylation frequency of BRD7 promoter in tumor biopsies and blood samples from NPC 
patients (A) as well as blood samples from corresponding normal individuals (B) by methylation-specific PCR. 
T: tumor biopsies, B: blood samples, N: blood samples from normal individuals, M: amplified product with primer recognizing 
methylated sequences, U: amplified product with primer recognizing unmethylated sequences.BMC Cancer 2008, 8:253 http://www.biomedcentral.com/1471-2407/8/253
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the interaction of transcription factors with their regula-
tory sequences or by attracting methylated DNA binding
proteins that, in turn, recruit histone deacetylases and his-
tone methyltransferases, resulting in an inactive chroma-
tin structure [19,20]. Our study indicates that DNA
methylation represses BRD7 gene transcription by directly
inhibiting the interaction of transcription factors with
their regulatory elements, as judged by the inability of TSA
to potentiate 5-Aza-CdR-mediated expression of BRD7
gene. Sp1 is a well-investigated factor that regulates tran-
scription through specific sequences in G/C-rich promoter
regions and is often critical for transcription initiation of
TATA-less promoters [21]. We identified several Sp1 bind-
ing sites in BRD7 promoter. Sp1 has high affinity to BRD7
promoter [16]. Sequence analysis of the bisulfite-modi-
fied BRD7 promoter demonstrated that cytosine residues
flanking functional Sp1 elements at -353/-337 and -330/-
317 are methylated. It is known that methylation of spe-
cific cytosine residues in or near transcription regulatory
motifs can block accessibility of the transcription factor
[22-24]. Indeed, we found that methylation of cytosines
flanking the -353/-337 and -330/-317 element impaired
the ability of nuclear protein to bind the Sp1 binding sites
in BRD7 promoter. Moreover, in vitro methylation of
BRD7 promoter construct with SssI methylase leads to an
almost complete loss of the activity of BRD7 promoter in
NPC cell lines. NPC is highly radiosensitive and chemo-
sensitive, but treatment of patients with locoregionally
advanced disease remains problematic [25,26]. New
biomarkers for NPC, including DNA copy number of EBV
or methylation of multiple tumour suppressor genes,
which can be detected in serum and nasopharyngeal
brushings, have been developed for the molecular diagno-
sis of this tumor. Recent findings suggest that epigenetic
inactivation of multiple tumor suppressor genes plays an
important role in the tumourigenesis of NPC, such as
aberrant methylation of the 5-CpG island of Ras associa-
tion domain family 1A (RASSF1A), RARβ2, death-associ-
ated protein kinase (DAP-kinase), p16 (CDKN2A), p15
(CDKN2B), p14 (ARF) and O6-methylguanine DNA
methyltransferase (MGMT), DLC1, TSLC1, TIG1 in NPC
[27-33]. In the present study, among the 18 NPC patients,
aberrant promoter methylation of BRD7 gene was
detected in 100% of tumor biopsies and matched blood
samples of NPC patients. In contrast, weak promoter
methylation of BRD7 gene was observed in half of the
blood samples from normal, healthy, age-matched indi-
viduals, indicating that epigenetic inactivation of BRD7
gene plays an important role in the tumorigenesis of NPC.
This is a provocative observation, suggesting that the
methylation status of BRD7 promoter may serve as a clin-
ical biomarker for early detection and prescreening
patients with clinical symptoms or individuals at high risk
as well as in monitoring patients for recurrence. Further
studies are necessary to confirm this.
Conclusion
BRD7 promoter demethylation is a prerequisite for high
level induction of BRD7 gene expression. DNA methyla-
tion of BRD7 promoter might serve as a diagnostic marker
in NPC.
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